- Home
- FINW vs CRVO Comparison
FINW vs CRVO Comparison
Compare FINW & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- CRVO
- Stock Information
- Founded
- FINW 1999
- CRVO 2001
- Country
- FINW United States
- CRVO United States
- Employees
- FINW N/A
- CRVO N/A
- Industry
- FINW Commercial Banks
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- CRVO Health Care
- Exchange
- FINW Nasdaq
- CRVO Nasdaq
- Market Cap
- FINW 170.0M
- CRVO 160.4M
- IPO Year
- FINW 2021
- CRVO N/A
- Fundamental
- Price
- FINW $14.31
- CRVO $19.17
- Analyst Decision
- FINW Buy
- CRVO Strong Buy
- Analyst Count
- FINW 1
- CRVO 4
- Target Price
- FINW $17.00
- CRVO $58.25
- AVG Volume (30 Days)
- FINW 12.3K
- CRVO 68.8K
- Earning Date
- FINW 10-24-2024
- CRVO 08-09-2024
- Dividend Yield
- FINW N/A
- CRVO N/A
- EPS Growth
- FINW N/A
- CRVO N/A
- EPS
- FINW 1.18
- CRVO N/A
- Revenue
- FINW $67,148,000.00
- CRVO $9,653,281.00
- Revenue This Year
- FINW N/A
- CRVO $47.04
- Revenue Next Year
- FINW $13.35
- CRVO N/A
- P/E Ratio
- FINW $12.15
- CRVO N/A
- Revenue Growth
- FINW 3.24
- CRVO 585.67
- 52 Week Low
- FINW $8.31
- CRVO $4.28
- 52 Week High
- FINW $14.98
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- FINW 74.87
- CRVO 55.34
- Support Level
- FINW $13.64
- CRVO $14.83
- Resistance Level
- FINW $13.25
- CRVO $17.43
- Average True Range (ATR)
- FINW 0.48
- CRVO 1.76
- MACD
- FINW 0.11
- CRVO 0.04
- Stochastic Oscillator
- FINW 92.54
- CRVO 73.22
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.